
Region:Asia
Author(s):Vijay Kumar
Product Code:KROD3711
December 2024
95

By Product Type: The Vietnam IVD market is segmented by product type into Reagents & Kits, Instruments, and Software & Services. Reagents and kits currently hold a dominant market share due to their recurring demand in diagnostic testing procedures, especially for clinical chemistry, hematology, and molecular diagnostics. The usage of reagents is essential for conducting various diagnostic tests, making them a critical consumable in clinical settings.

By Technology: The Vietnam IVD market is segmented by technology into Immunoassay/Immunochemistry, Molecular Diagnostics, Clinical Chemistry, Hematology, Microbiology, and Others. The molecular diagnostics segment has emerged as the fastest-growing technology due to its capability for early and precise detection of infectious and chronic diseases. Molecular diagnostics techniques such as PCR and next-generation sequencing are extensively used in cancer diagnostics, genetic testing, and infectious disease testing.

The Vietnam IVD market is dominated by several key players, both global and local. The market is highly consolidated, with the top companies accounting for a significant share of the overall market revenue. Major players are focusing on product innovation, strategic alliances, and geographical expansion to strengthen their market positions. The Vietnam IVD market is currently led by multinational companies such as Abbott, Danaher, and Roche Diagnostics, which have established robust distribution networks and strong customer relationships.

Over the next five years, the Vietnam In-Vitro Diagnostics (IVD) market is expected to witness steady growth, driven by rising demand for advanced diagnostic technologies, expansion of healthcare infrastructure, and an increasing geriatric population that necessitates more frequent health check-ups. Government initiatives aimed at expanding diagnostic capabilities and reducing the burden of chronic diseases will further support the market's growth trajectory. Technological advancements in areas such as point-of-care testing and molecular diagnostics will play a pivotal role in enhancing the market's value.
|
Product Type |
Instruments Reagents and Kits Software and Services |
|
Technology |
Immunoassay/Immunochemistry Molecular Diagnostics Clinical Chemistry Hematology Microbiology Others |
|
Application |
Infectious Diseases Oncology Cardiology Nephrology Others |
|
End User |
Hospitals and Clinics Diagnostics Laboratories Point-of-Care Testing Centers Academic and Research Institutes |
|
Region |
Northern Vietnam Central Vietnam Southern Vietnam |
1.1. Definition and Scope
1.2. Market Taxonomy
1.3. Market Growth Rate
1.4. Market Segmentation Overview
1.5. Impact of COVID-19 on the Vietnam IVD Market
1.6. Government Initiatives and Regulations
2.1. Historical Market Size
2.2. Current Market Size Analysis
2.3. Year-on-Year Growth Analysis
2.4. Key Market Developments and Milestones
3.1. Growth Drivers
3.1.1. Rising Prevalence of Chronic Diseases (e.g., Diabetes, Cardiovascular Diseases, Cancer)
3.1.2. Growing Geriatric Population
3.1.3. Technological Advancements in IVD Solutions
3.2. Market Challenges
3.2.1. High Initial Investment in Advanced Diagnostics
3.2.2. Regulatory Compliance and Certification Processes
3.2.3. Limited Awareness in Rural Areas
3.3. Opportunities
3.3.1. Adoption of Point-of-Care Testing (POCT) Solutions
3.3.2. Expansion of Healthcare Infrastructure in Central and Southern Vietnam
3.3.3. International Partnerships for R&D and Manufacturing
3.4. Trends
3.4.1. Increased Use of Molecular Diagnostics
3.4.2. Adoption of Digital Health and AI in Diagnostics
3.4.3. Growing Focus on Personalized Medicine
3.5. Government Regulations
3.5.1. Decree No. 98/2021 on Medical Equipment Management
3.5.2. Implementation of ASEAN Medical Device Directive (AMDD)
3.5.3. Marketing Authorization Code (MAC) Requirements for Class C and D Devices
3.6. SWOT Analysis
3.7. Porters Five Forces Analysis
3.8. Competition Ecosystem
3.9. Stakeholder Ecosystem and Strategic Initiatives
4.1. By Product Type (In Value %)
4.1.1. Instruments
4.1.2. Reagents and Kits
4.1.3. Software and Services
4.2. By Technology (In Value %)
4.2.1. Immunoassay/Immunochemistry
4.2.2. Molecular Diagnostics
4.2.3. Clinical Chemistry
4.2.4. Hematology
4.2.5. Microbiology
4.2.6. Others (Coagulation, Urinalysis)
4.3. By Application (In Value %)
4.3.1. Infectious Diseases
4.3.2. Oncology
4.3.3. Cardiology
4.3.4. Nephrology
4.3.5. Others (Autoimmune Diseases, Drug Testing)
4.4. By End User (In Value %)
4.4.1. Hospitals and Clinics
4.4.2. Diagnostics Laboratories
4.4.3. Point-of-Care Testing Centers
4.4.4. Academic and Research Institutes
4.5. By Region (In Value %)
4.5.1. Northern Vietnam
4.5.2. Central Vietnam
4.5.3. Southern Vietnam
5.1. Detailed Profiles of Major Companies
5.1.1. Abbott Laboratories
5.1.2. Danaher Corporation
5.1.3. Siemens Healthineers AG
5.1.4. Roche Diagnostics
5.1.5. Sysmex Corporation
5.1.6. Bio-Rad Laboratories
5.1.7. Becton Dickinson and Company
5.1.8. Thermo Fisher Scientific
5.1.9. Quidel Corporation
5.1.10. PerkinElmer Inc.
5.1.11. Ortho Clinical Diagnostics
5.1.12. Qiagen N.V.
5.1.13. BioMrieux S.A.
5.1.14. Hologic Inc.
5.1.15. Agilent Technologies
5.2. Cross Comparison Parameters (Revenue, Market Share, Product Portfolio, Key Strategic Initiatives, R&D Expenditure)
5.3. Market Share Analysis
5.4. Strategic Initiatives (Mergers, Acquisitions, Partnerships)
5.5. Investment Analysis
5.6. Government Grants and Funding
5.7. Private Equity Investments and Venture Capital Funding
6.1. Regulatory Requirements for IVD Devices
6.2. Classification of IVD Devices (Class A, B, C, D)
6.3. Compliance with ASEAN Medical Device Directives (AMDD)
6.4. Certification and Licensing Processes
7.1. Future Market Size Projections
7.2. Key Factors Driving Future Market Growth
7.3. Expected Developments and Innovations
8.1. Market Expansion Strategies
8.2. Strategic Partnerships for Innovation
8.3. Product Differentiation and Customization
8.4. Regulatory Compliance and Risk Management
Disclaimer Contact UsThe initial phase involves constructing an ecosystem map encompassing all major stakeholders within the Vietnam In-Vitro Diagnostics Market. This step is underpinned by extensive desk research, utilizing a combination of secondary and proprietary databases to gather comprehensive industry-level information. The primary objective is to identify and define the critical variables that influence market dynamics.
In this phase, we compile and analyze historical data pertaining to the Vietnam In-Vitro Diagnostics Market. This includes assessing market penetration, the ratio of marketplaces to service providers, and the resultant revenue generation. Furthermore, an evaluation of service quality statistics will be conducted to ensure the reliability and accuracy of the revenue estimates.
Market hypotheses will be developed and subsequently validated through computer-assisted telephone interviews (CATIs) with industry experts representing a diverse array of companies. These consultations provide valuable operational and financial insights directly from industry practitioners, which are instrumental in refining and corroborating the market data.
The final phase involves direct engagement with multiple IVD manufacturers to acquire detailed insights into product segments, sales performance, consumer preferences, and other pertinent factors. This interaction serves to verify and complement the statistics derived from the bottom-up approach, ensuring a comprehensive, accurate, and validated analysis of the Vietnam In-Vitro Diagnostics market.
The Vietnam In-Vitro Diagnostics (IVD) market is valued at USD 226 million, based on a five-year historical analysis. This market is primarily driven by an increasing burden of chronic diseases, including diabetes, cardiovascular diseases, and cancer, necessitating more frequent and advanced diagnostic solutions.
Challenges include stringent regulatory requirements under Decree No. 98/2021, high initial investment costs for advanced diagnostic equipment, and limited awareness of diagnostic solutions in rural and underserved regions.
Major players include Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Roche Diagnostics, and Sysmex Corporation, all of which have a strong presence in the Vietnam market due to their extensive product portfolios, strategic alliances, and distribution networks.
The primary growth drivers are the rising geriatric population, the increasing burden of chronic diseases, and advancements in diagnostic technologies. The adoption of point-of-care testing and molecular diagnostics is significantly contributing to market growth.
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.